Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane

Reporter: J Taylor Whaley
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de junio del 2012

Translation for this article does not exist

Blogs

Smoothies for All Occasions
by OncoLink Editorial Team
May 24, 2016